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ABSTRACT
Human induced pluripotent stem cells (iPSCs) reprog-
rammed from somatic cells represent a promising unlim-
ited cell source for generating patient-speciﬁc cells for
biomedical research and personalized medicine. As a ﬁrst
step, critical to clinical applications, we attempted to de-
velop deﬁned culture conditions to expand and differenti-
ate human iPSCs into functional progeny such as
dopaminergic neurons for treating or modeling Parkin-
son’s disease (PD). We used a completely deﬁned (xeno-
free) system that we previously developed for efﬁcient gen-
eration of authentic dopaminergic neurons from human
embryonic stem cells (hESCs), and applied it to iPSCs.
First, we adapted two human iPSC lines derived from dif-
ferent somatic cell types for the deﬁned expansion medium
and showed that the iPSCs grew similarly as hESCs in the
same medium regarding pluripotency and genomic stabil-
ity. Second, by using these two independent adapted iPSC
lines, we showed that the process of differentiation into
committed neural stem cells (NSCs) and subsequently into
dopaminergic neurons was also similar to hESCs. Impor-
tantly, iPSC-derived dopaminergic neurons were func-
tional as they survived and improved behavioral deﬁcits in
6-hydroxydopamine-leasioned rats after transplantation.
In addition, iPSC-derived NSCs and neurons could be efﬁ-
ciently transduced by a baculoviral vector delivering epi-
somal DNA for future gene function study and disease
modeling using iPSCs. We also performed genome-wide
microarray comparisons between iPSCs and hESCs, and
we derived NSC and dopaminergic neurons. Our data
revealed overall similarity and visible differences at a mo-
lecular level. Efﬁcient generation of functional dopaminer-
gic neurons under deﬁned conditions will facilitate
research and applications using PD patient-speciﬁc iPSCs.
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INTRODUCTION
Parkinson’s disease (PD) is a common and ultimately incapa-
citating disease with no cure. The main pathological hallmark
of PD is a progressive loss of substantia nigra dopaminergic
neurons in the midbrain. The availability of human embryonic
stem cells (hESCs) and methods for in vitro differentiation of
dopaminergic neurons from hESCs [1–4], animal models of
PD, and previous encouraging results from fetal transplants
have raised the possibility that one may be able to manufac-
ture human dopaminergic neurons from hESCs in unlimited
quantities in vitro. Indeed, we and others have provided evi-
dence for a scalable good manufacture practice (GMP) pro-
cess that will allow one to obtain dopaminergic neurons from
multiple hESC lines [5].
The recently acquired ability to reprogram human adult
somatic cells to induced pluripotent stem cells (iPSCs) in cul-
ture [6] has raised the possibility that not only could we pro-
vide allogenic dopaminergic neurons but also now provide an
unlimited source of personalized cells for replacement ther-
apy. Human iPSCs thus may allow us to bypass the immunor-
ejection issue faced with allogenic cell transplants and may
also solve bioethical concerns surrounding hESCs. As PD
may be either hereditary or acquired, iPSC lines derived from
such patients could also serve as a unique tool for drug
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applications. Several key issues, however, need to be
addressed before iPSC-based therapy can become prevalent.
This requires extending the development of deﬁned cell cul-
ture systems developed for hESC-derived dopaminergic neu-
rons, conﬁrming that iPSC lines are overall similar to hESCs,
and developing zero footprint iPSC induction technology and
efﬁcient gene delivery as well as retargeting methodologies.
Although there are few side by side comparisons directed
at revealing subtle differences between ESCs and iPSCs, pub-
lished results so far, largely conﬁrm that irrespective of the
path to pluripotency, the cells behave virtually similarly to
each other. Nevertheless, some differences have been
observed. The frequency of karyotypic abnormalities in iPSCs
seems to be higher than in ESCs. Anecdotal evidence also
suggests that teratomas from iPSCs appear less complex and
more cystic. The frequency and extent of chimerism with
mouse iPSCs is more limited and there appear biases depend-
ing on the cell of origin of the pluripotent population. More
recently, differences between iPSCs and ESCs in gene expres-
sion have been reported [7], however, whether these differen-
ces are signiﬁcant and wider than normal allelic differences
remains to be seen.
Ultimately, it is important to address fundamental issues
such as whether human iPSCs can efﬁciently differentiate into
therapeutically relevant cells like dopaminergic neurons as
hESCs can, and whether such cells are functional both in vitro
and in vivo. Although neurons expressing tyrosine hydroxy-
lase (TH) have been generated from human iPSCs [8, 9] and
functional dopaminergic neurons have been derived from
mouse iPSCs [10], it remains unknown whether authentic sub-
stantia nigra (A9) dopaminergic neurons can be efﬁciently
generated from human iPSCs, and whether such cells will
function in vivo for potential cell therapy. Thus, there is a
lack of robust culture systems for efﬁcient generation of func-
tional A9 dopaminergic neurons from human iPSCs.
In this study, we have validated a scalable protocol for ef-
ﬁcient generation of A9 dopaminergic neurons from multiple
iPSC lines using a completely deﬁned xeno-free system that
we have developed for hESC differentiation [5]. Using this
procedure, we showed that neural stem cells (NSCs) derived
from two human iPSC lines adapted to deﬁned media were
able to differentiate into functional dopaminergic neurons
similar to hESCs in terms of time course, neural patterning,
and efﬁciency of generation of dopaminergic neurons. Side by
side comparison of iPSCs and hESCs as well as of iPSC- and
hESC-derived NSCs and dopaminergic neurons revealed that
iPSCs were overall similar to hESCs in gene expression pro-
ﬁles. In addition, we showed that iPSC-derived dopaminergic
neurons could improve symptoms of PD in a preclinical
rodent model, and be genetically modiﬁed efﬁciently. Our
approach will facilitate subsequent adaptation of protocols to
GMP standards which is a prerequisite for progression toward
clinical trials.
MATERIALS AND METHODS
Cell Culture
The iPSC lines MR31 (derived from IMR90 fetal lung ﬁbro-
blasts) and MMW2 (derived from adult mesenchymal stem
cells from bone marrow) were derived as described [11]. At
passages 10 and 15, cells were adapted to a completely
humanized-base medium consisting of StemPro hESC me-
dium with 20% human Knockout Serum Replacement
(hKSR), 1  StemPro protein cocktail and 8 ng/ml of basic
ﬁbroblast growth factor (FGF2) on culture dishes coated with
CellStart, a xeno-free deﬁned substrate (all from Invitrogen,
Carlsbad, CA http://www.invitrogen.com) [5]. Cells were split
every 4–6 days using a cell scraper and karyotyped every 10
passages. hESC culture was obtained as described previously
[5].
Derivation of NSCs from iPSCs in Deﬁned Media
iPSC colonies (>10 passages in deﬁned medium with a nor-
mal karyotype) were harvested using a scraper and cultured in
suspension as embryoid bodies (EBs) for 8 days in StemPro
deﬁned medium minus FGF2. EBs were then cultured for
additional 2–3 days in suspension in neural induction medium
containing Dulbecco’s Modiﬁed Eagle Medium (DMEM/F12)
with Glutamax, NEAA, N2, and FGF2 (20 ng/ml) prior to
attachment on cell culture plates coated with CellStart. Neural
rosettes formed 2–3 days after adherent culture were isolated
manually using stretched glass Pasteur pipette and placed in
fresh culture dishes. Then, the rosettes were dissociated into
single cells using accutase and replated onto culture dishes to
obtain a homogeneous population of NSCs. The NSCs popu-
lation was expanded in Neurobasal media containing NEAA,
2 mM glutamine, B27, and 20 ng/ml FGF2.
To conﬁrm that NSCs can differentiate into astrocytes,
NSCs were cultured in DEMEM/F12 medium supplemented
with 1  NEAA, L-glutamine (2 mM), 1  N2, and 1  B27
for 2 weeks and processed for immunostaining. To initiate
oligodendrocyte differentiation, NSCs were cultured in me-
dium containing DMEM/F12, 1  NEAA, L-glutamine (2
mM), 1  N2, 1  B27, Shh (200 ng/ml, R&D Systems), and
retinoic acid (RA; 2 lM) for 10 days, and then with NT3 (30
ng/ml, R&D Systems) and platelet-derived growth factor
alpha (PDGFa) (10 ng/ml, R&D Systems) but without Shh
and RA for an additional 2 weeks.
Dopaminergic Differentiation of NSCs
Dopaminergic differentiation in deﬁned media was initiated
by culturing NSCs for 10 days in neurobasal medium supple-
mented with NEAA, L-glutamine (2 mM), B27, Shh (200 ng/
ml), and FGF8 (100 ng/ml). Shh and FGF8 were then with-
drawn and replaced with Brain-derived neurotrophic factor
(BDNF) and Glial cell-derived neurotrophic factor (GDNF)
(20 ng/ml of each), Transforming growth factor beta-3
(TGFb3) (1 lM), ascorbic acid (200 lM), and cAMP (1 mM)
for 3 weeks ( 30 days after the NSC stage).
Immunocytochemistry
Immunocytochemistry and staining procedures were as
described previously [12]. Brieﬂy, hESCs at different stages
of dopaminergic differentiation were ﬁxed with 2% parafor-
maldehyde for half an hour. Fixed cells were blocked in
blocking buffer (10% goat serum, 1% BSA, 0.1% Triton X-
100) for 1 hour followed by incubation with the primary anti-
body at 4 C overnight in 8% goat serum, 1% BSA, 0.1% Tri-
ton X-100. Appropriately coupled secondary antibodies (Mo-
lecular Probes, Carlsbad, CA http://www.invitrogen.com/site/
us/en/home/brands/Molecular-Probes.html) were used for sin-
gle and double labeling. All secondary antibodies were tested
for cross reactivity and nonspeciﬁc immunoreactivity. The fol-
lowing primary antibodies were used: Oct4 (ab19857 AbCam,
Cambridge, MA http://www.abcam.com) 1:1,000; b-Tubulin
isotype III clone SDL.3D10 (T8660 Sigma, St. Louis, MO
http://www.sigmaaldrich.com/united-states.html) 1:500; GalC
(MAB342 Millipore, Billerica, MA http://www.millipore.com)
1894 Human iPSC-Derived Dopaminergic Neurons1:50; Glial ﬁbrillary acidic protein (GFAP) (M0761 Chemi-
con) 1:50; Nestin (611658 BD Transduction laboratories)
1:500; Sox1 (AB5768 Chemicon Billerica, MA http://
www.millipore.com) 1:800, TH (Pel-freez, Rogers, AR http://
www.pelfreez-bio.com P40101) 1:500, TH clone TH-16
(T2928 Sigma) 1:1,000; Girk2 (Alamone) 1:250; Musashi
(eBioscience, San Diego, CA http://www.ebioscience.com)
1:50, and as secondary antibodies: Alexa Fluor 488 Goat
Anti-Mouse, Alexa Fluor 594 Goat Anti-Mouse, Alexa Fluor
488 Goat Anti-Rabbit, Alexa Fluor 594 Goat Anti-Rabbit.
Hoechst 33342 (Molecular Probes H3570) 1:1,000 were used
for nuclei identiﬁcation. Images were captured on a Nikon
ﬂuorescence microscope.
The quantiﬁcation of TH
þ cells in culture was performed
by analyzing ﬂuorescent images using Photoshop on a mini-
mum of 5,000 cells of at least 10 randomly chosen ﬁelds
derived from three or more independent experiments. The
number of Hoechst-labeled nuclei on each image was referred
as total cell number (100%).
Gene Expression by Microarray and Polymerase
Chain Reaction Analysis
RNAs isolated from ESC/iPSC, NSCs, and dopaminergic pop-
ulations were hybridized to Illumina Human HT-12 BeadChip
(Illumina, Inc., San Diego, CA; performed by Microarray
core facility at the Burnham Institute for Medical Research).
Array data processing and analysis was performed using Illu-
mina BeadStudio software. The Illumina array data were nor-
malized by the background method. The maximum expression
value for probe set of one gene was chosen as the expression
value of this gene. Using the processed data, we conducted
Global array clustering of genes across all the hESC/iPSC,
NSC, and dopaminergic samples, using the complete linkage
method and measuring the Euclidean distance. The result was
presented by a dendrogram. Differentially expressed gene was
deﬁned if the gene showed twofold expression change
between any two samples. The data of differentially expressed
genes were transformed to log2 signal values for each gene
across all samples. Unsupervised two-way hierarchical cluster-
ing of differentially expressed genes was analyzed with The
Institute for Genomic Research Multiexperiments Viewer
(MEV) v4.5.1 [13], which used complete linkage and Euclid-
ean distance metric to generate the hierarchical tree. High
expressions relative to mean are colored red, whereas low
expressions are colored green. Black represents no signiﬁcant
change in expression level between mean and sample. All cell
line correlations were a measure of Pearson’s rho imple-
mented in Statistical Analysis System (SAS).
cDNA was synthesized by using a reverse transcription kit
SuperScript III First-Strand Synthesis System for Real Time
Polymerase chain reaction (RT-PCR) (Invitrogen) according
to the manufacturer’s recommendations. Real-time polymerase
chain reaction (PCR) was used to quantify the levels of
mRNA expression of 10 genes in day 32 dopaminergic popu-
lations. PCR reactions were carried out by ABI 900HT instru-
ment according to the manufacturer’s instructions. Primer
sequences were previously described [5].
Baculovirus Preparation and Transduction
Baculoviral vector carrying a GFP driven by the Cytomegalo-
virus (CMV) promoter was obtained from Life Technologies
and viral particles were prepared accordingly to manufacture’s
instruction. For transduction, NSCs were infected with baccu-
loviral particles at ratio of 500–1,000 Multiplicity of Infection
(MOI) for 30 minutes at room temperature on a rocker. Trans-
duced cells were plated on culture dishes without virus re-
moval and cultured over night at 37 C. Viral particles were
removed by a medium change next day. Neurons in adherent
culture were transduced at the ratio as above and were incu-
bated with the viral particles over night at 37 C. Medium was
changed the next day.
Transplantation into the 6-Hydroxydopamine Rats,
Behavioral and Histological Analyses
Fourteen rats were anesthetized and 20 lg of 6-hydroxydopa-
mine (6-OHDA; Sigma-Aldrich) were stereotaxically injected
at a concentration of 4 lg/ll (in 0.2 mg/ml ascorbate in sa-
line) at one site in the MFB (stereotaxic coordinates: antero-
posterior,  4.4 mm; mediolateral,  1.2 mm; dorsoventral,
 7.8 mm) using a Hamilton syringe. The toxin was injected
at a rate of 1 ll/minute. To ensure complete lesion of the ni-
grostriatal DA pathway, the animals were screened by am-
phetamine-induced rotation at a dose of 2.5 mg/kg. Only ani-
mals [10] that exhibited a mean ipsilateral rotation score of
seven or more complete body turns per minute were included
in the study.
For rational behavior analysis, the animals were given 2.5
mg/kg D-amphetamine intraperitoneally, and their rotational
behavior was monitored over a 90-minute period using the
rotameter system (TSE) (Bad Homburg, Germany). Rotation
toward the lesion (ipsilateral) was scored as positive and net
rotational asymmetry score were expressed as full body turns
per minute.
For histological analysis, brains were removed and immer-
sion-ﬁxed overnight at room temperature. Brains were then
dehydrated in graded ethanol, cleared in xylene, and parafﬁn-
embedded [14]. Seven micrometer-thick serial coronal sec-
tions were cut and mounted on glass slides, which were dried
overnight at 42 C. Sections were deparafﬁnized, rehydrated
through a graded series of ethanol, and washed in water. For
immunostaining [15], sections were incubated with blocking
solution (2% horse serum, 1% bovine serum albumin, and
0.1% Triton X-100 in phosphate-buffered saline, pH 7.5) and
then with primary antibodies at 4 C overnight followed by
secondary antibodies in blocking solution at room temperature
for 2 hours. The primary antibodies used were rabbit anti-TH
antibody (1:500; Pel-freez, Rogers, AR http://www.pelfreez-
bio.com, P40101) and mouse anti-human nuclear antibody
(1:300; Chemicon Billerica, MA http://www.millipore.com,
MAB 1281). The secondary antibodies were rhodamine-conju-
gated rat-absorbed donkey anti-rabbit IgG (Jackson Immu-
noResearch Laboratories, West Grove, PA http://www.
jacksonimmuno.com; 1:200) and ﬂuorescein isothiocyanate-
conjugated pig anti-mouse IgG (Vector Laboratories Burlin-
game, CA http://www.vectorlabs.com; 1:200). Nuclei were
counterstained with 40,6-diamidino-2-phenylindole using pro-
Long Gold antifade reagent (Invitrogen, Carlsbad, CA http://
www.invitrogen.com). To quantitatively analyze double-la-
beled neurons in the striatum, ﬂuorescence signals were
detected with an LSM 510 NLO Confocal Scanning System
mounted on an Axiovert 200 inverted microscope (Carl Zeiss
Ltd Maple Grove, MN http://www.zeiss.com) equipped with a
two-photon Chameleon laser (Coherent Inc Santa Clara, CA
http://www.coherent.com). Three-color images were scanned
using Argon and 543 HeNe lasers. IMARIS (Bitplane AG,
Zurich Switzerland, http://www.bitplane.com) imaging soft-
ware was used for three-dimensional image reconstruction.
Images were acquired using LSM 510 Imaging Software (Carl
Zeiss Ltd Maple Grove, MN http://www.zeiss.com) as
described previously [15]. The speciﬁcity of each label was
ﬁrst veriﬁed using single-channel scans that were then merged
Swistowski, Peng, Liu et al. 1895
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1896 Human iPSC-Derived Dopaminergic Neuronsinto multiple-channel views. Neurons were considered double-
labeled if colabeling with relevant morphology was seen
throughout the extent of the nucleus for nuclear markers or if
a cytoplasmic marker surrounds a nuclear marker when
viewed in x-y cross section as well as in x-z and y-z cross-sec-
tions produced by orthogonal reconstructions from z-stacks
taken at  400 magniﬁcation. Human antigen single-labeled
neurons and neurons double-labeled for TH and human anti-
gen were recorded in every seventh section per animal (n ¼
3). The area of each transplanted region was simultaneously
determined for each of the scored sections.
RESULTS
Adaption of Multiple iPSC Lines to Deﬁned Media
and Generation of NSCs from Adapted iPSCs
We have previously shown that hESCs can be maintained in
a xeno-free environment and induced to differentiate into
NSCs and subsequently to authentic dopaminergic neurons
using animal origin-free components by a four-step scalable
protocol [5]. To test whether iPSCs could be adapted to
deﬁned medium culture while retained genetic integrity and
maintained the ability to generate multipotent NSCs after pro-
longed culture, we cultured and differentiated two human
iPSC lines MMW2 and MR31 using identical components as
for hESCs. The MMW2 line was derived from adult mesen-
chymal stem cells by the standard four retroviral vectors
expressing the four factors, Oct4, Sox2, Klf4, and c-Myc
[11]. The MR31 line was reprogrammed by only three factors
(omitting c-myc) from human fetal ﬁbroblasts [16]. Both lines
were shown to be pluripotent and karyotypically normal [17].
To adapt iPSCs to a deﬁned medium culture, early MR31
and MMW2 lines (at passages 10–15) were continuously cul-
tured in StemPro medium (a chemically deﬁned medium) on a
deﬁned substrate (CellStart) for over 10 passages. As seen in Fig-
ure 1A–1D, like hESCs, both iPSC lines grown in deﬁned me-
dium expressed pluripotentcy markers such as Oct4, TRA-1-60
and SSEA4, and maintained a normal karyotype in prolonged
culture. No differences were observed in the course of adaption
regarding morphological characteristics between hESCs and
iPSCs. As the results are similar for both iPSC lines, staining
images of only one of the lines (MR31) are shown here.
To generate NSCs, feeder-free deﬁned medium cultured
iPSC colonies were detached and cultured in suspension as EBs
i nad e ﬁ n e dm e d i u mf o l l o w e db ya d h e r e dc u l t u r e .B o t hi P S C
lines formed neural tube-like rosette structures morphologically
undistinguishable from those differentiated from hESCs (Fig.
1E). These rosette-derived cells uniformly expressed NSC
markers nestin, Sox1, and musashi (Fig. 1G–1H), but not differ-
entiated neuronal (e.g., b-III tubulin) or glial markers (GFAP or
O4; data not shown). We did not observe signiﬁcant differences
between the two iPSC lines and the hESCs regarding the efﬁ-
ciency of generation of neural rosettes and NSCs. Furthermore,
NSCs that were expanded in deﬁned medium for over 10 pas-
sages maintained a normal karyotype and the expression of NSC
markers Sox1 nestin and musashi. They also retained the ability
to differentiate into neurons, astrocytes, and oligodendrocytes
(Fig. 1I–1L). This result indicates that similar to hESCs, iPSCs
adapted to deﬁned medium differentiate into neural cells under
deﬁned conditions.
iPSC-Derived NSCs Differentiated Efﬁciently into
Dopaminergic Neurons in Deﬁned Conditions
One of the major goals of using iPSCs for personalized medi-
cine and disease modeling is to generate therapeutically target
cells such as functional neurons of specialized neurotransmit-
ter phenotype. We have previously shown that several hESC
lines differentiate efﬁciently and similarly into authentic dopa-
minergic neurons using our xeno-free deﬁned protocol [5],
and therefore, we wish to address whether iPSC-derived
NSCs can differentiate into functional dopaminergic neurons
using an identical protocol.
Treatment of iPSC-derived NSCs with Shh and FGF8 for
10 days followed by GDNF and BDNF for 3 weeks resulted
in an efﬁcient differentiation to dopaminergic neurons as a
large numbers of cells expressed TH by immunocytochemis-
try (Fig. 2A–2C). For both iPSC lines, approximately 30% 6
5% of total cells were positive for TH, which was compris-
able to the efﬁciency seen in hESC-derived NSC differentia-
tion [5]. Importantly, nearly 100% of the TH-expressing neu-
rons coexpressed nigral marker Girk2 (Fig. 2D), indicating
that these neurons were of A9 dopaminergic neurons. Expres-
sion of additional midbrain and dopaminergic markers in
iPSC-derived neurons was also assessed by real-time quantita-
tive PCR. As expected, several markers including En1, Otx2,
Lamx1b, Msx1, Nurr1, Lmx1b, Aromatic L-Amino Acid De-
carboxylase (AADC), Vesicular Monoamine Transporter
(VMAT), and dopamine transporter (DAT) were upregulated
in dopaminergic populations compared with the expression in
NSCs (Fig. 2E).
iPSC-Derived Dopaminergic Neurons Survived
and Ameliorate Behavioral Deﬁcits in 6-OHDA
PD Rats
To investigate whether dopaminergic neurons derived from
iPSCs exhibited functional properties, we transplanted the
MR31-derived cells (20 days after the NSC stage) into 6-
OHDA rats and conducted behavioral and histological studies,
which we viewed as minimal criteria for assessing dopaminer-
gic neuronal function. We ﬁrst examined the behavior of
sham-operated rats and rats received iPSC-derived dopaminer-
gic neurons. As seen in Figure 3A, control rats that were
transplanted with medium showed no attenuation of ampheta-
mine-induced rotary behavior over the course of the experi-
ment (12 weeks), whereas rats that were transplanted with
grafts demonstrated signiﬁcant rotational improvement at 12
weeks after transplantation (p < .05). Histological analysis
revealed that donor cells (human antigen-immunopositive
cells) coexpressing TH were found in all brains throughout
the graft sites at 12 weeks (end of experiment) following the
transplantation (Fig. 3B–3E). Cell counts in serial sections
from one representative animal showed that the graft con-
tained approximately 2,106 6 313 TH-positive cells/mm
3
human antigen-positive cells (donor-derived cells). This num-
ber of donor-derived dopaminergic neurons survived in the
grafts was comparable with transplants with hESC-derived do-
paminergic neurons [5]. We did not observe any structures
resembling teratoma-like tissues by thorough histological
analyses in the grafts in any animals regardless of receiving
medium alone or iPSC-derive cells. Overall, these results
were similar to what has been reported for hESC-derived cells
transplanted in the same 6-OHDA rat PD model, indicating
that iPSC-derived cells can survive in vivo and can ameliorate
behavioral deﬁcits in PD rats.
Gene Expression Proﬁling of hESCs, iPSCs, and
Cells Differentiated from Them
To further test the utility of iPSC-derived cells, we conducted
a side by side whole genomic comparison of iPSCs and
hESCs during dopaminergic differentiation using the deﬁned
medium protocol described earlier. Cells were harvested at
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a transcriptome analysis was performed using Illumina arrays
and pathways analysis software as described in ‘‘Materials
and Methods’’ section and previously [18]. hESC data pre-
sented in this article is similar to previous analysis for the
same population at a different passage number allowing for
future comparisons of discrete data sets. The current analysis
was limited to this data set (A total of nine samples: undiffer-
entiated hESC line H9, iPSC lines MR31 and MMW2, NSCs
derived from H9, MR31 and MMW2, and day 31 dopaminer-
gic neurons derived from H9, MR31, and MMW2).
Correlation clustering was performed to show that iPSCs
were overall similar to hESCs rather than to differentiated
cells, and NSC and dopaminergic neurons differentiated from
them appeared more similar to each other. The overall corre-
lation coefﬁcient between each population was calculated by
Pearson’s rho (Table 1) and presented by a dendrogram analy-
sis (Fig. 4A). This is consistent with our immunological and
functional analysis, which suggests that iPSCs differentiate
using similar cues and signals as hESCs, and that the overall
process of differentiation and the end phenotype are similar to
hESC-derived products.
Figure 2. Efﬁcient differentiation of induced pluripotent stem cell (iPSC)-derived NSCs into dopaminergic neurons. (A–D): iPSC-derived NSCs
differentiated into midbrain dopaminergic neurons in deﬁned media as seen by immunocytochemistry. The majority of the cells expressed b-III-
tubulin and TH after 5 weeks of differentiation (A–C). Coexpression of A9 marker Girk2 in TH
þ dopaminergic neurons (D). Differential expres-
sion of dopaminergic markers in dopaminergic neurons compared with NSCs by quantitative polymerase chain reaction (E). All the examined
markers were upregulated in dopaminergic populations compared with NSCs. Abbreviations: AADC, Aromatic L-Amino Acid Decarboxylase;
DAT, dopamine transporter; NSC, neural stem cell; TH, tyrosine hydroxylase.
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pluripotent stem cell (iPSC)-derived
cells into 6-hydroxydopamine (6-
OHDA) Parkinson’s disease (PD) rats.
iPSC-derived dopaminergic neurons
engrafted and ameliorated behavioral
deﬁcits in a PD model. (A): Ampheta-
mine-induced rotations in 6-OHDA rats
grafted with iPSC-derived neurons (20
days after the neural stem cell stage)
showed signiﬁcant rotational improve-
ment 12 weeks after transplantation.
(B–E): Histological analysis of a
representative brain section showed that
donor cells (human antigen-immunopos-
itive cells) coexpressing TH survived in
the graft sites 12 weeks post-transplan-
tation. Abbreviation: TH, tyrosine
hydroxylase.
Table 1. Correlation coefﬁcients (R
2) of paired samples on the microarray
Samples/R
2a ESC_H9 iPSC MMW2 iPSC MR31 NSC H9 NSC MMW2 NSC MR31 DA_H9 DA MMW2 DA MR31
ESC_H9 N/A 0.976 0.966 0.915 0.932 0.91 0.801 0.808 0.807
iPSC_MMW2 0.976 N/A 0.977 0.932 0.949 0.935 0.831 0.833 0.832
iPSC_MR31 0.966 0.977 N/A 0.934 0.939 0.93 0.862 0.861 0.843
NSC_H9 0.915 0.932 0.934 N/A 0.983 0.975 0.888 0.905 0.888
NSC_MMW2 0.932 0.949 0.939 0.983 N/A 0.977 0.863 0.881 0.876
NSC_MR31 0.91 0.935 0.93 0.975 0.977 N/A 0.877 0.901 0.883
DA_H9 0.801 0.831 0.862 0.888 0.863 0.877 N/A 0.93 0.905
DA_MMW2 0.808 0.833 0.861 0.905 0.881 0.901 0.93 N/A 0.965
DA_MR31 0.807 0.832 0.843 0.888 0.876 0.883 0.905 0.965 N/A
aCorrelation coefﬁcients (R
2) of paired samples were a measure of Pearson’s rho.Abbreviations: DA, dopaminergic; iPSC, induced
pluripotent stem cell; NSC, neural stem cell.
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Table 2. As expected, many pluripotency genes including
Oct4, Nanog, and Sox2 were highly expressed in iPSCs and
hESCs. Of the genes shown, little difference was seen
between the two iPSC lines and hESC line H9. The differen-
ces observed were similar in magnitude to those seen in com-
parisons among different hESC lines and the same line grown
in different laboratories [18].
Given the different path to pluripotency and methods of dif-
ferentiation, we looked at the expression of some genes/pathways
that we and others have suggested might be different between
hESCs and iPSCs such as genes involved in imprinting, cell
cycle regulation, and reprogramming. Examination of imprinted
genes which we thought may be different shows a small number
of differences (Supporting Information Table 1). These included
maternally expressed DLK1 and H19, and paternally expressed
DLX5 and PEG3. It has been previously noted that the cell cycle
in ESCs (pRb and p53 in particular) is regulated differently than
in other somatic cell population [19]. Little difference at the tran-
scriptome level was observed between the two iPSC lines and
H9, suggesting that as cells transited to the iPSC state their cell
cycle regulation changed appropriately. Likewise, the expression
level of iPSC inducing genes (the three or four reprogramming
factors) in the iPSC lines was comparable with H9 suggesting
the exogenous induced genes had been silenced. Surprisingly,
unlike other reports, we did not observe signiﬁcant expression of
ﬁbroblast or mesodermal markers in undifferentiated iPSCs.
A more detailed analysis of the process of differentiation
was performed by examining NSC gene expression comparisons
and comparisons after cells had been differentiated to dopaminer-
gic neurons. An unsupervised two-way hierarchical cluster analy-
sis of differentially expressed genes across ESC/iPSC, NSCs,
and dopaminergic neuron samples is also shown in Figure 4B.
As expected, the heat map shows a clear separation of ESC/
iPSC, NSC, and dopaminergic cell types, and a separation of six
differentially expressed gene clusters in different colors. The
hESCs and iPSCs types were strongly associated with cluster six
(yellow), which was upregulated in hESCs and iPSCs, whereas
downregulated in the other cell types. The red genes (cluster 1
and cluster 2) appear to be dopaminergic-speciﬁc, which were
upregulated in the dopaminergic cells, whereas downregulated or
expressed at low levels in undifferentiated and NSC samples.
More speciﬁcally, Table 2 shows the expression levels of four
markers representative of NSCs in iPSC- and hESC-derived
NSC populations. No signiﬁcant difference was observed among
the lines. Of the 20 genes associated with dopaminergic/neuronal
speciﬁcation, differentiation, and maturation, or PD listed in Ta-
ble 2, many of them including EN1, Nurr1, TH, AADC, and
Girk2 were upregulated in dopaminergic populations derived
from both the iPSCs and hESCs. Nevertheless, differences in
expression of some genes among the lines were observed. These
include SNCA, NGFR, MAOB, MAOA, TFAP2A, and COMT.
Baculoviral Vector-Mediated Gene Transduction in
iPSC-Derived NSCs and Neurons
One potential application of iPSCs is disease modeling. For
the study of neurodegenerative disorders it is crucial to be
able to introduce and express exogenous constructs in neuro-
nal cells to assess gene function. Like other postmitotic cells,
neurons present a particular challenge regarding the efﬁciency
of gene transfer. To achieve efﬁcient transduction in human
neurons, we have developed a platform technology that uti-
lizes an insect virus backbone (baculovirus) to deliver large
payloads. Using this novel episomal baculoviral-based vector
system (a nonintegrating gene delivery strategy), we tested
this delivery system with a ubiquitous promoter (CMV) driv-
ing GFP in iPSC-derived NSCs and their differentiated neu-
rons. As seen in Figure 5A and 5B, approximately 87% NSCs
were expressing GFP 24 hours after transduction as assessed
by Fluorescence-Activated Cell Sorting (FACS) analysis.
Likewise, transduction is efﬁcient in iPSC-derived neurons
(36 days after NSC differentiation) as 90.3% of cells
expressed GFP 2 days after transduction (Fig. 5C, 5D). Trans-
duction in hESC-derived neurons was shown as comparison
(Fig. 5E, 5F, 5J–5L). Immunostaining of b-III tubulin con-
ﬁrmed that the majority of neurons coexpressed GFP (Fig.
5G–5L). Importantly, expression of transgene in postmitotic
neurons was maintained for at least 3 weeks, demonstrating
the usefulness of this technology in genetic modiﬁcation of
human neurons including iPSC-derived neurons.
DISCUSSION
A possible therapeutic approach to curing PD is to generate
immune compatible dopaminergic neurons by reprogramming
somatic cells (e.g., skin ﬁbroblasts or blood cells) from PD
patients and then differentiating them into dopaminergic neu-
rons. To do this in a clinically compliant manner, it is
Figure 4. Whole genomic analysis of iPSCs at different stages of
dopaminergic differentiation by Illumina bead microarray. A total of
nine samples (undifferentiated human embryonic stem cell [hESC]
line H9, iPSC lines MR31 and MMW2, NSCs derived from H9,
MR31, and MMW2, and dopaminergic neurons derived from H9,
MR31, and MMW2) were analyzed by Illumina array and the results
demonstrated similarities between hESC and iPSCs. (A): Dendrogram
of unsupervised one-way hierarchical clustering analysis of global
gene expression data in hESCs/iPSCs, NSCs, and dopaminergic neu-
rons derived from hESCs/iPSCs. (B): Unsupervised two-way hierarch-
ical cluster analysis of differentially expressed genes illustrated in a
heat map. The samples include three groups, hESCs/iPSCs, NSCs,
and dopaminergic neurons. Expression values are presented as the
log2 signal value of the given gene. Abbreviations: DA, dopaminer-
gic; iPSC, induced pluripotent stem cell; NSC, neural stem cell.
1900 Human iPSC-Derived Dopaminergic Neuronsimportant to show that scalable methods of GMP-compatible
cell culture exist, and that iPSC lines are overall similar to
hESCs so that the body of existing literature on hESCs can be
utilized. It is equally important to show that iPSC lines can
be obtained from disease models of PD, and that these lines
can be propagated and differentiated appropriately, and used
for comparative analysis. Finally, it is also important to show
that a stage(s) where the effect of a mutation can be assessed
and that the mutation can be corrected or a mechanism be
identiﬁed.
In this article, we showed that iPSC lines derived from
different somatic cell populations can be grown in a hESC-
based protocol using a xenogenic-free deﬁned medium and
differentiation protocol optimized for hESCs. Using this 4-
step scalable process (propagation of hESCs ! generation of
NSCs ! induction of dopaminergic precursors ! maturation
of dopaminergic neurons), we tested two iPSC lines derived
from different somatic cells (adult ﬁbroblast and mesenchy-
mal stem cell) and generated NSCs and subsequently dopami-
nergic neurons from them. We showed that each of the manu-
facturing steps could be performed using xeno-free deﬁned
conditions in iPSCs similar to hESCs. Neurons generated by
this process appeared to be authentic A9 dopaminergic neu-
rons as assessed by in vitro (marker expression) and in vivo
(transplantation in PD animal model) assays. This observation
was not entirely unexpected as it has been observed that the
reprogramming factors are not needed forever. Indeed, once
the cells are reprogrammed, they express endogenous pluripo-
tency genes and silence the exogenous ones. Thus, like ESCs
or other pluripotent cells, iPSCs should readily differentiate
into appropriate lineages and respond in a manner indistin-
guishable from ESCs. Indeed, this observation has been uti-
lized cleverly by several groups to develop zero-footprint
technology [20, 21] that allows one to reprogram somatic
Table 2. Expression of genes representative of pluripotency or associated with NSC or dopaminergic differentiation in iPSCs/ESCs and their
neural derivatives
Gene
ESC or iPSC NSC Dopaminergic neuron
H9 MMW2 MR31 H9 MMW2 MR31 H9 MMW2 MR31
Pluripotency markers
NANOG 3,896 4,095 3,118 ND ND ND ND 12 10
UTF1 76 142 147 ND ND ND ND ND ND
OCT4 15,860 12,398 9,696 ND 13 23 27 3 6
SOX2 8,858 13,609 12,635 13,000 18,362 18,146 8,544 10,501 8,514
CD9 749 825 656 ND 43 25 ND 10 99
ZFP42 5,344 1,340 5,125 6 12 5 14 24 9
LEFTY1 10,874 12,668 4,547 17 ND ND 79 27 38
GAL 6,516 7,108 4,120 11 57 39 44 102 99
GRB7 816 730 1,079 2 23 13 4 9 1
LEFTY2 6,754 2,416 2,217 33 10 10 10 ND 2
FOXD3 426 133 221 11 ND ND 223 256 5
DIAPH2 8,936 3,615 5,689 259 469 828 211 256 64
IFITM1 13,169 11,319 13,970 382 968 1,725 24 160 164
NODAL 1,958 992 792 74 64 55 ND 46 24
TDGF1 168 157 164 13 ND 27 14 ND ND
GDF3 428 365 511 38 53 ND ND ND 287
DNMT3B 18,551 21,424 20,549 1,715 1,962 2,944 1,366 1,230 713
PODXL 25,112 30,793 22,130 4,270 4,343 2,283 574 591 673
NSC markers
MUSASHI-1 330 735 443 1,734 2,281 3,949 1,655 2,136 1,145
NESTIN 3,982 3,818 2,059 9,280 13,126 10,997 7,622 5,285 3,577
SOX1 ND 5 ND 35 64 126 16 20 ND
SOX2 8,858 13,609 12,635 13,000 18,362 18,146 8,544 10,501 8,514
Dopaminergic/neuronal markers
b-III tubulin 6,276 7,742 5,565 23,727 25,727 21,806 32,618 42,030 51,117
NEUROG1 ND 25 27 56 74 617 517 370 1
NEUROG2 3 26 40 360 559 4,761 3,336 28,68 443
GFRA1 33 43 28 555 559 978 585 452 228
GFRA2 164 188 195 194 285 177 643 893 2,337
NURR1 20 73 256 49 48 24 226 416 1,938
EN1 18 ND 4 104 134 3 111 79 200
TH 25 14 258 6 4 27 373 794 704
AADC 17 16 ND 86 84 70 65 394 73
GIRK2 77 316 132 159 227 24 408 519 540
MAOB ND 36 23 ND 2 11 27 161 190
MAOA 212 339 314 74 69 42 27 819 1,238
PINK1 197 371 533 412 232 324 1,430 1,122 1,602
SNCAIP 242 293 317 1,526 1,357 1,977 3,872 2,821 3,265
DRD1IP 85 121 147 40 138 244 1,789 5,382 7,355
PMP2 3 17 ND 8 7 ND 1,380 4,287 4,109
SNCA 495 1,313 1,174 511 1,566 1,262 1,749 6,665 8,203
NGFR ND ND ND 32 ND 13 283 34 96
TFAP2A 374 1,693 1,223 236 168 190 16 514 595
COMT 2,429 953 2,186 2,345 2,296 2,054 1,050 3,188 77
Abbreviations: iPSC, induced pluripotent stem cell; ND, not detected; NCS, neural stem cell.
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1902 Human iPSC-Derived Dopaminergic Neuronscells using factors or genes that can then be permanently
eliminated leaving cells that theoretically, at least, should be
indistinguishable from ESCs derived in a conventional fash-
ion, and thus media and reagents developed for ESCs should
work with iPSCs.
Our results of directly comparing hESCs with iPSCs suggest
that it is true that iPSCs are similar to hESCs. Both functional
studies and transcriptome analyses suggest that overall iPSCs
derived from somatic cells are largely similar to hESCs. We
focused our transcriptome analysis in particular on selected
pathways that we and others have suggested may be different
between ESCs and iPSCs given the different histories of the
ancestor cell that generates a pluripotent population. These
include maternal and paternal allele-speciﬁc gene expression
(imprinting), cell cycle, and senescence, and subtle biases in dif-
ferentiation due to the source of cells and incomplete reprog-
ramming. Although we did not detect any signiﬁcant differen-
ces, we emphasize that subtle biases are probably best tested in
competitive functional assays. Our transplant results suggest
that this may be a useful model in which mixed labeled popula-
tions can be transplanted in a competitive assay akin to that
descried earlier by Jaenisch and coworkers where they showed
mouse iPSCs differentiated into functional neurons and glia af-
ter transplantation into the developing brain [10].
Given the overall similarity and the ability to bypass the
immune response, interest in using iPSCs for therapy has been
high. Recently, iPSC lines from sporadic PD patients have been
generated [8] and several groups have now shown that gene tar-
geting can be performed with roughly the same efﬁciency as in
hESCs, and that iPSCs from people carrying known mutations
can be harvested and propagated [22, 23]. Although PD is usu-
ally sporadic, genetic studies have, however, identiﬁed muta-
tions in several genes, including LRRK2, parkin, a-synuclein,
uchL1, PINK1, DJ-1,a n dATP13A2, in familial PD. We, there-
fore, initiated an effort to generate iPSC lines from familial PD
patients with deﬁned mutations. As a proof-of-principle experi-
ment, we derived an iPSC line from skin biopsies obtained
from a PD patient with a deﬁned mutation in LRRK2 as muta-
tions in LRRK2 account for approximately 7% of familial PD
cases and a signiﬁcant portion of sporadic PD cases [24, 25].
Using the identical differentiation protocol, we derived Sox1
þ/
Nestin
þ NSCs from the LRRK2 iPSC line. Further analysis of
potential phenotype during dopaminergic differentiation associ-
ated with the mutation in familial PD patient lines is the scope
of our future work.
Full utilization of iPSCs for personalized medicine and
disease modeling requires the development of methods of
efﬁcient genetic modiﬁcation including gene targeting and
efﬁcient expression or reporters. Recently, it has been shown
that gene targeting in iPSCs can be achieved by homologous
recombination mediated by zinc ﬁnger nucleases [22, 23].
Efﬁcient gene transfer in iPSC-derived differentiated cells
such as neurons would be valuable for both therapy and
gene discover, but has been a challenge because of the difﬁ-
culty of transfecting postmitotic cells. Nonviral physical- or
chemical-based methods such as electroporation, nucleofec-
tion, and lipofection are inefﬁcient in transfecting postmi-
totic cells [26]. Viral vectors such as lentiviral and retroviral
systems can transduce neurons with high efﬁciency, but are
primarily used for stable genomic modiﬁcation and transduc-
tion is associated with random integration of transgene.
Here, we used an episomal baculoviral-based vector to
achieve efﬁcient expression of transgene in iPSC-derived
NSCs and particularly in postmitotic neurons. This noninte-
gration method of high efﬁciency transfection in human neu-
rons may enhance the utilization of iPSCs for disease mod-
eling as it provides a powerful tool to study neuronal cell
biology.
In conclusion, we believe that we have provided strong
evidence of the utility of the iPSCs approach to both gene
discovery and therapy.
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